Guest Editors
Assoc. Prof. Wenjie Shi
Email: wenjie.shi@uol.de
Affiliation: Department of General, Visceral, Vascular and Transplant Surgery, University of Magdeburg, Magdeburg, Germany
Homepage:
Research Interests: breast cancer, colon cancer, pancreatic cancer
Prof. Dr. Rudy Leon De Wilde
Email: rudyleon.dewilde@pius-hospital.de
Affiliation: Clinic for Obstetrics and Gynecology, Pius-Clinic Oldenburg, University of Gottingen, Gottingen, Germany
Homepage:
Research Interests: tumor marker, radiomics, durg resistance
Summary
Therapeutic resistance remains one of the most formidable challenges in the treatment of solid tumors, severely limiting the efficacy of targeted therapies, chemotherapy, radiotherapy, and immunotherapy. Both primary resistance and secondary (acquired) resistance that arises during treatment are driven by highly complex mechanisms, including genetic and epigenetic alterations, pronounced tumor heterogeneity, signaling pathway rewiring, and adaptive reprogramming of the tumor microenvironment. These processes act in concert, leading to reduced therapeutic efficacy, disease progression, and a markedly increased risk of recurrence. In recent years, the rapid development of cutting-edge technologies has provided unprecedented tools and conceptual frameworks for dissecting resistance mechanisms. For example, transcriptomic and single-cell sequencing have revealed cellular heterogeneity and evolutionary trajectories; artificial intelligence (AI)-driven radiogenomics has enabled deep integration of imaging features with molecular biomarkers; and organoid-based model systems have offered powerful platforms for functional validation and individualized drug screening. Collectively, these emerging technologies not only advance a systematic understanding of therapeutic resistance but also provide a solid theoretical foundation and technical support for the development of novel therapeutic strategies.
This Special Issue aims to consolidate cutting-edge research on therapeutic resistance in solid tumors, with particular attention to multi-omics integration, AI-driven radiogenomics, and organoid-based functional platforms. Emphasis will be placed on the discovery and rigorous validation of novel resistance-associated biomarkers, with the ultimate goal of informing the development of innovative therapeutic paradigms and accelerating their translation into clinical practice.
Themes includes but is not limited to:
· Mechanistic studies of therapy resistance in solid tumors;
· Identification and validation of novel therapeutic targets;
· Application of cutting-edge technologies to resistance profiling;
· Development and evaluation of new therapeutic combinations;
· Advances in modeling resistance using organoids;
· Novel clinical strategies to overcome therapeutic resistance;
· Systems biology, multi-omics integration, and biomarker discovery.
Keywords
drug resistance, neoplasm, solid tumors, omics, novel targets, precision medicine
Login
Register
Submit a Paper
Propose a Special lssue